CN104428001A — Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2015-03-18 · 11y expired
What this patent protects
本发明揭示用于治疗需要所述治疗的患者的非BRAFV600E突变体黑素瘤的方法。所述方法包含向所述患者投与MEK抑制剂，例如(R)-3-(2,3-二羟基丙基)-6-氟-5-((2-氟-4-碘苯基)氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮(TAK-733)；和RAF抑制剂，其选自N-{7-氰基-6-[4-氟-3-({[3-(三氟甲基)苯基]乙酰基}氨基)苯氧基]-1,3-苯并噻唑-2-基}环丙烷甲酰胺(TAK-632)和(R)-2-(1-(6-氨基-5-氯嘧啶-4-甲酰胺基)乙基)-N-(5-氯-4-(三氟甲基)吡啶-2-基)噻唑…
USPTO Abstract
本发明揭示用于治疗需要所述治疗的患者的非BRAFV600E突变体黑素瘤的方法。所述方法包含向所述患者投与MEK抑制剂，例如(R)-3-(2,3-二羟基丙基)-6-氟-5-((2-氟-4-碘苯基)氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮(TAK-733)；和RAF抑制剂，其选自N-{7-氰基-6-[4-氟-3-({[3-(三氟甲基)苯基]乙酰基}氨基)苯氧基]-1,3-苯并噻唑-2-基}环丙烷甲酰胺(TAK-632)和(R)-2-(1-(6-氨基-5-氯嘧啶-4-甲酰胺基)乙基)-N-(5-氯-4-(三氟甲基)吡啶-2-基)噻唑-5-甲酰胺(MLN2480)。本发明还揭示了用于治疗所述黑素瘤的药物。
Drugs covered by this patent
- Ojemda (TOVORAFENIB) · Day One Biopharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.